What is the 13F Pro Quality Score for NVST?

13F Pro ranks Envista Holdings Corp (NVST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NVST's current score at https://13fpro.ai/company/NVST (free sign-up required for the full ranking).

Which hedge funds own the most NVST stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NVST include BlackRock,, ARIEL INVESTMENTS,, DIMENSIONAL FUND ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/NVST as soon as new 13F filings post.

Where does 13F Pro source NVST data?

All Envista Holdings Corp fundamentals and ownership data come directly from SEC EDGAR. Envista Holdings Corp files with the SEC under CIK 1757073. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NVST in?

Envista Holdings Corp (NVST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives NVST's revenue?

Per Envista Holdings Corp's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Specialty Products & Technologies ($471.0M, +5.8% YoY); Equipment & Consumables ($259.5M, +9.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/NVST.

What are NVST's largest expenses?

Envista Holdings Corp's latest 10-Q reports these as the largest expense items: Cost of sales ($323.5M, +3.6% YoY); Selling, general and administrative ($296.3M, +0.3% YoY); Research and development ($30.4M, +7.4% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended July 3, 2026).

How often is NVST research updated on 13F Pro?

NVST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Envista Holdings Corp(NVST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1757073 NVST stock profile & AI dashboard →

13F Pro Quality Score

54.9/100

Rank #1,290 of 2,960 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

45.9/100

Profitability

48.0/100

Balance Sheet

50.6/100

Earnings Quality

91.1/100

Free Cash Flow

52.7/100

Institutional Flow

30.9/100

Revenue Scale

68.8/100

Dilution Risk

48.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NVST Scores 55/100

exact factor attribution · 2026-09-12

NVST's composite is driven by earnings quality and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+4.1 pts

91th pct

Scale

+2.8 pts

69th pct

Free cash flow

+0.4 pts

53th pct

Capital efficiency

+0.1 pts

51th pct

Shareholder dilution

-0.1 pts

48th pct

Profitability

-0.3 pts

48th pct

Earnings growth

-0.3 pts

43th pct

Revenue growth

-0.8 pts

46th pct

Institutional flow

-1.0 pts

31th pct

Latest change (2026-08-05): 50 → 51 · ↑ Earnings growth 8→33

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NVST Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for Envista Holdings Corp (NVST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVST at 54.9/100 on a 32-signal composite quality model, placing it at rank #1,290 of 2,960 stocks — the top half of the AI-ranked universe. NVST scores in the top quartile across earnings quality (91.1). Areas of concern include institutional flow (30.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 48.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Envista Holdings Corp reports quarterly revenue of $730.5M, net income of $53.7M, an operating margin of 11.0%. Top institutional holders of NVST by reported 13-F value include BlackRock, ARIEL INVESTMENTS, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. NVST trades on the NYSE exchange and files with the SEC under CIK 1757073. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Envista Holdings Corp directly from SEC EDGAR. Envista Holdings Corp's 13F Pro composite quality score has ranged between 35 and 59 since 2021, currently 54.9 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.

✦

Fun facts about Envista Holdings Corp

Quirks, history, and lore behind NVST — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mid-cap · listed on the NYSE · headquartered in California.
2
The Numbers
Annual revenue in the range of $2.5–3 billion, with operations spanning more than 100 countries — most people have never heard of it, but their dentist almost certainly has.
3
The History
Spun off from Danaher Corporation in 2019, it was assembled from a collection of well-established dental technology businesses that Danaher had acquired over the years.
4
The Secret
Its portfolio covers the full arc of a dental visit — from imaging and diagnostics to implants and orthodontics — essentially a one-stop shop for the dental office supply chain.
5
The Lore
Its brands include Nobel Biocare, one of the most recognized names in dental implants, and Ormco, a major player in orthodontic brackets and wires.
6
The Giveaway
If your smile has ever been straightened, implanted, or X-rayed, there's a solid chance this Danaher dental spinout — ticker NVST — had something to do with it.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving NVST's Business? Latest 10-Q Breakdown

✓ 21/21 datapoints verified

AI-extracted from Envista Holdings Corp's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended July 3, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Envista Q2 revenue grew 7.1% to $730.5M with operating profit surging 73.4% to $80.3M, driven by 5.0% core sales growth and $12.6M in tariff refunds.

Biggest Revenue Drivers

Specialty Products & Technologies$471.0M+5.8% YoY

Dental implant systems, regenerative solutions, orthodontic brackets, and aligners grew from volume increase of 2.0% and price increase of 1.1%.

Equipment & Consumables$259.5M+9.5% YoY

Digital imaging systems, endodontic systems, restorative materials grew from volume increase of 5.5% and price increase of 3.0%.

Biggest Revenue Drivers

Total revenue: $730.5M+7.1% YoY

Specialty Products & Technologies$471.0M+5.8% YoY

Dental implant systems, regenerative solutions, orthodontic brackets, and aligners grew from volume increase of 2.0% and price increase of 1.1%.

Equipment & Consumables$259.5M+9.5% YoY

Digital imaging systems, endodontic systems, restorative materials grew from volume increase of 5.5% and price increase of 3.0%.

Largest Expense Items

Cost of sales$323.5M+3.6% YoY

Higher sales drove additional $13.5M in product costs; partially offset by $12.6M tariff refunds received.

Selling, general and administrative$296.3M+0.3% YoY

$7.2M increase in commercial growth initiatives offset by $3.2M property sale gain and $1.6M lower intangible amortization.

Research and development$30.4M+7.4% YoY

Higher investment in new product innovation to support future growth.

Margins: Gross margin expanded 150 basis points to 55.7% from 54.2%, driven by operational leverage on higher sales and tariff refund benefits. Operating margin improved significantly to 11.0% from 6.8%, reflecting gross profit gains and SG&A deleveraging.

Watch Items from the Filing

Largest customer represents 13% of total sales for Q2 2026, compared to 11% prior year, indicating modest customer concentration increase.
Tariff exposure remains; company received $12.6M refund in Q2 under Phase 1 IEEPA refund process for ~$30M paid tariffs, with timing and recoverability of remaining refunds uncertain.
Versah acquisition ($54.7M) in February 2026 integrated into Specialty Products segment; goodwill recognized of $20.9M, contributing to operating leverage gains.
Foreign currency headwind: 54.5% of Q2 sales from outside US; currency translation added 1.6% to reported growth but generated $6.8M other comprehensive loss.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$730.5M

Net Income

Q2 2026

$53.7M

Free Cash Flow

Q2 2026

$104.3M

Operating Margin

Q2 2026

11.0%

ROIC

Q2 2026

7.1%

D/E Ratio

Q2 2026

0.47

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.3% YoY

$2.72BFY 2025

FY22 $2.57BFY23 $2.57BFY24 $2.51BFY25 $2.72B

Net Income

+104.2% YoY

$47.0MFY 2025

FY22 $243.1MFY23 $-100.2MFY24 $-1.12BFY25 $47.0M

Operating Income

+120.8% YoY

$216.1MFY 2025

FY22 $319.2MFY23 $31.5MFY24 $-1.04BFY25 $216.1M

EPS (Diluted)

+104.3% YoY

$0.28FY 2025

FY22 $1.37FY23 $-0.60FY24 $-6.50FY25 $0.28

Total Assets

+6.1% YoY

$5.68BFY 2025

FY22 $6.59BFY23 $6.61BFY24 $5.35BFY25 $5.68B

Total Debt

-10.9% YoY

$1.45BFY 2025

FY22 $2.40BFY23 $1.74BFY24 $1.63BFY25 $1.45B

Op. Cash Flow

-18.1% YoY

$275.7MFY 2025

FY22 $182.7MFY23 $275.7MFY24 $336.5MFY25 $275.7M

Free Cash Flow

-23.9% YoY

$230.4MFY 2025

FY22 $107.0MFY23 $217.5MFY24 $302.7MFY25 $230.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.72B +8.3%	$2.51B -2.2%	$2.57B -0.1%	$2.57B +2.4%	$2.51B +30.1%	$1.93B
Net Income	$47.0M +104.2%	$-1.12B -1016.4%	$-100.2M -141.2%	$243.1M -28.6%	$340.5M +922.5%	$33.3M
Operating Income	$216.1M +120.8%	$-1.04B -3395.9%	$31.5M -90.1%	$319.2M +4.2%	$306.2M +603.9%	$43.5M
EPS (Diluted)	$0.28 +104.3%	$-6.50 -983.3%	$-0.60 -143.8%	$1.37 -28.6%	$1.92 +860.0%	$0.20
Total Assets	$5.68B +6.1%	$5.35B -19.0%	$6.61B +0.3%	$6.59B +0.2%	$6.57B -4.4%	$6.88B
Total Debt	$1.45B -10.9%	$1.63B -6.7%	$1.74B -27.4%	$2.40B +10.1%	$2.18B -38.9%	$3.57B
Operating Cash Flow	$275.7M -18.1%	$336.5M +22.1%	$275.7M +50.9%	$182.7M -49.5%	$361.6M +27.4%	$283.9M
Free Cash Flow	$230.4M -23.9%	$302.7M +39.2%	$217.5M +103.3%	$107.0M -65.1%	$306.9M +29.9%	$236.2M

Get alerted when NVST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Envista Holdings Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NVST

BlackRock, Inc.
$485.8M18,437,542 sh
ARIEL INVESTMENTS, LLC
$258.7M9,818,177 sh
DIMENSIONAL FUND ADVISORS LP
$252.1M9,566,949 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$197.3M7,487,670 sh
VANGUARD CAPITAL MANAGEMENT LLC
$193.4M7,337,916 sh
MORGAN STANLEY
$169.6M6,436,043 sh
Gates Capital Management, Inc.
$146.3M5,552,383 sh
STATE STREET CORP
$140.5M5,329,275 sh
ALLIANCEBERNSTEIN L.P.
$132.3M5,213,644 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$127.7M4,847,940 sh

Fund	Value	Shares
BlackRock, Inc.	$485.8M	18,437,542
ARIEL INVESTMENTS, LLC	$258.7M	9,818,177
DIMENSIONAL FUND ADVISORS LP	$252.1M	9,566,949
VANGUARD PORTFOLIO MANAGEMENT LLC	$197.3M	7,487,670
VANGUARD CAPITAL MANAGEMENT LLC	$193.4M	7,337,916
MORGAN STANLEY	$169.6M	6,436,043
Gates Capital Management, Inc.	$146.3M	5,552,383
STATE STREET CORP	$140.5M	5,329,275
ALLIANCEBERNSTEIN L.P.	$132.3M	5,213,644
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$127.7M	4,847,940

Companies Similar to NVST

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

HAE

HAEMONETICS CORP

AI score

Similar quality profile · 26 shared holders

ARIEL INVESTMENTS, LLC Boston Partners Wellesley Asset Management

ELAN

Elanco Animal Health Inc

AI score

Similar quality profile · 19 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.FRONTIER CAPITAL MANAGEMENT CO LLC JUPITER ASSET MANAGEMENT LTD

EYE

National Vision Holdings, Inc.

AI score

Similar quality profile · 11 shared holders

JUPITER ASSET MANAGEMENT LTD Boston Partners First Eagle Investment Management, LLC

CNMD

CONMED Corp

AI score

Similar quality profile · 11 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.OAKTREE CAPITAL MANAGEMENT LP Calamos Advisors LLC

AMRX

Amneal Pharmaceuticals, Inc.

AI score

Similar quality profile · 12 shared holders

Parkman Healthcare Partners LLC Cinctive Capital Management LP Oliver Luxxe Assets LLC

ALHC

Alignment Healthcare, Inc.

AI score

Similar quality profile · 15 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)OBERWEIS ASSET MANAGEMENT INC/ROYCE & ASSOCIATES LP

PBH

Prestige Consumer Healthcare Inc.

AI score

Similar quality profile · 18 shared holders

ARIEL INVESTMENTS, LLC FULLER & THALER ASSET MANAGEMENT, INC.Leeward Investments, LLC - MA

BMRN

BIOMARIN PHARMACEUTICAL INC

AI score

Similar quality profile · 21 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)CAMDEN ASSET MANAGEMENT L P /CA Defilade Capital Management, L.P.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NVST on your watchlist

Track score changes the day Envista Holdings Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NVST a good stock to buy?

13F Pro's AI-powered analysis of Envista Holdings Corp (NVST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVST are available on the NVST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NVST is classified as a mid company.

Which hedge funds own NVST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Envista Holdings Corp's investment landscape.